TORONTO and GLIL YAM, Israel, Jan. 26, 2026 /PRNewswire/ -- IM Cannabis Corp. ("IMC" or the "Company") (Nasdaq: IMCC), a leading medical cannabis company with operations in Israel and Germany, today announced that it has raised a total of US$2,171,660.40 in debt financings from an arm's length third party (the "Lender") in order to manage the Company's current liquidity requirements. First Note Pursuant to a note purchase agreement between the Company and Lender dated January 7, 2026 (the "First Note Purch ...

Core Insights - IM Cannabis Corp. has appointed Mr. Alon Dayan to its board of directors effective December 31, 2025, enhancing its leadership team with expertise in technology and business development [1][2]. Company Overview - IM Cannabis Corp. is an international medical cannabis company that provides premium cannabis products to medical patients in Israel and Germany, focusing on sustainable and profitable growth in these high-value markets [3]. - The company operates a transnational ecosystem powered by a data-driven approach and a globally sourced product supply chain, aiming to amplify its commercial and brand power in the global cannabis market [3]. Operations - In Israel, IM Cannabis operates through subsidiaries that import and distribute cannabis to medical patients, utilizing proprietary data and patient insights [4]. - The company also runs medical cannabis retail pharmacies and online platforms in Israel to ensure safe delivery and quality control of its products throughout the value chain [4]. - In Germany, IM Cannabis operates through Adjupharm GmbH, distributing cannabis to pharmacies for medical cannabis patients [4].

Core Insights - IM Cannabis Corp. has appointed Asi Levi as the new Chief Financial Officer, effective immediately, replacing Uri Birenberg [1][3] - Asi Levi brings over 15 years of finance experience, having held CFO roles in various companies and expertise in fundraising, financial planning, and compliance with international financial reporting standards [2] Company Overview - IM Cannabis Corp. is a leading international cannabis company focused on providing premium cannabis products to medical patients in Israel and Germany, which are significant markets for medical cannabis [4] - The company aims for sustainable and profitable growth by leveraging a data-driven approach and a globally sourced product supply chain, while adhering to strict regulatory standards [4] - The IMC ecosystem includes subsidiaries in Israel that import and distribute cannabis, operate retail pharmacies, and manage logistics to ensure quality control and safe delivery of products [5]

Core Insights - IM Cannabis Corp. reported its financial results for Q3 2025, indicating a transition year with potential regulatory challenges in Germany affecting sales [2][4] - The company recorded a non-cash impairment of $3.1 million in Q3 2025, impacting its financial performance [2][11] - Revenue for Q3 2025 remained stable at $13.9 million, consistent with Q3 2024, while total revenue for the first nine months of 2025 was $39 million, down from $40.7 million in the same period of 2024 [11][17] Financial Performance - Gross profit for Q3 2025 was $2.7 million, a decrease of 13% compared to $3.1 million in Q3 2024 [11] - Gross margin decreased to 20% in Q3 2025 from 23% in Q3 2024, reflecting a 13% decline [11] - Operating expenses rose significantly to $6.9 million in Q3 2025, up 68% from $4.1 million in Q3 2024, primarily due to the impairment [11] Losses and Adjusted Metrics - The net loss for Q3 2025 was $3.9 million, compared to a net loss of $1.1 million in Q3 2024, with the increase attributed to the impairment [11] - Adjusted EBITDA loss for Q3 2025 was $0.6 million, worsening from a loss of $0.2 million in Q3 2024, marking a 143% decline [11] - Basic and diluted loss per share increased to $0.75 in Q3 2025 from $0.41 in Q3 2024 [11] Balance Sheet Overview - Total assets as of September 30, 2025, were $44.3 million, up 13% from $39.2 million at the end of 2024, driven by increases in inventory and advances to suppliers [11] - Total liabilities increased to $40 million as of September 30, 2025, an 11% rise from $36 million at the end of 2024, mainly due to higher accounts payable [11] - Cash and restricted cash on hand were $2.3 million as of September 30, 2025, compared to $0.9 million at the end of 2024 [11]

Core Insights - IM Cannabis Corp. is set to report its operational and financial results for Q3 2025 on November 13, 2025, before market opening [1] Company Overview - IM Cannabis Corp. is an international cannabis company focused on providing premium cannabis products to medical patients in Israel and Germany, which are among the largest medical cannabis markets [2] - The company aims for sustainable and profitable growth in its key markets, leveraging a data-driven approach and a globally sourced product supply chain [2] - IM Cannabis is committed to responsible growth and compliance with strict regulatory environments to enhance its commercial and brand power [2] Operational Ecosystem - The IMC ecosystem operates in Israel through subsidiaries that import and distribute cannabis to medical patients, utilizing proprietary data and patient insights [3] - The company manages medical cannabis retail pharmacies, online platforms, distribution centers, and logistical hubs in Israel to ensure safe delivery and quality control of its products [3] - In Germany, IM Cannabis operates through Adjupharm GmbH, distributing cannabis to pharmacies for medical cannabis patients [3]

Core Points - IM Cannabis Corp. announced the resignation of Chief Financial Officer Uri Birenberg for personal reasons, effective January 5, 2026, or earlier if determined by the company [1] - The CEO of IM Cannabis expressed gratitude for Birenberg's contributions over the past two years and wished him success in his future endeavors [2] - Birenberg stated his pleasure in serving as CFO and expressed confidence in the company's future [2] Company Overview - IM Cannabis Corp. is an international medical cannabis company operating in Israel and Germany, focusing on providing premium cannabis products to medical patients [3] - The company utilizes a data-driven approach and a globally sourced product supply chain to enhance its commercial and brand power [3] - IM Cannabis operates through subsidiaries in Israel, importing and distributing cannabis, and also runs medical cannabis retail pharmacies and distribution centers [4] - In Germany, the company distributes cannabis to pharmacies through its subsidiary Adjupharm GmbH [4]

Industry Overview - The cannabis industry is evolving with potential U.S. federal reform and international market expansion, leading to increased global demand for both medical and recreational cannabis [1] - Analysts project the U.S. cannabis market could exceed $50 billion by 2030, driven by growing legalization efforts and shifting consumer attitudes [1] - Navigating this sector requires careful attention to fundamentals, technical analysis, and disciplined risk management [1] Company Highlights IM Cannabis Corp. (IMCC) - IM Cannabis is an international medical cannabis company headquartered in Israel, focusing on the medical market through pharmacy networks and online distribution [3][5] - The company reported a notable increase in annual revenue in 2024, reflecting rising medical demand in Israel and Germany, with modest revenue growth and a small net profit in Q1 2025 [5][11] - IM Cannabis represents a stable, lower-risk option for investors seeking medical cannabis exposure with a strong international foundation [5] Cronos Group Inc. (CRON) - Cronos Group is a Canadian cannabinoid company with a global strategy, focusing on both recreational and medical markets [6][8] - The company reported solid year-over-year revenue growth, supported by strong Canadian adult-use sales and expanding global demand, with improved gross profit margins [8] - Cronos maintains one of the strongest balance sheets in the cannabis industry, providing flexibility for future acquisitions or U.S. market entry [8][11] Aurora Cannabis Inc. (ACB) - Aurora Cannabis is one of Canada's largest cannabis producers, serving both recreational and medical markets with a wide international footprint [9][10] - The company reported significant revenue growth year-over-year, driven by rising medical sales and improved distribution efficiency, with a return to consistent profitability [10][11] - Aurora remains one of the few large-scale producers generating sustainable profits in the global cannabis space, appealing to investors looking for scale and stability [10][11]

Core Viewpoint - IM Cannabis Corp. has signed a non-binding indicative term sheet to acquire a 60% equity interest in a quantum computing bio data company for up to $54 million, aiming to enhance long-term growth opportunities and shareholder value [1][4]. Company Overview - IM Cannabis Corp. is a leading medical cannabis company operating in Israel and Germany, focusing on premium cannabis products for medical patients in these significant markets [6][7]. - The company aims for sustainable and profitable growth by leveraging a data-driven approach and a globally sourced product supply chain [6]. Proposed Transaction Details - The acquisition involves an aggregate consideration of up to $54 million, which will be paid in cash, IMC shares, and potential earn-out payments based on performance milestones [2]. - The transaction is subject to due diligence, negotiation of definitive agreements, and necessary corporate and regulatory approvals [3]. Strategic Intent - This move follows the company's decision to explore additional business activities to enhance growth opportunities and create further shareholder value [4].

Board Changes - IM Cannabis Corp. announced the resignation of Messrs. Shmulik Arbel and Brian Schinderle from the Board, Audit Committee, and Compensation Committee effective September 15, 2025 [1][2] - Messrs. Asaf Yitzhaik and Eli Zamir have been appointed to the Board and the Audit Committee to fill the vacancies created by the resignations, with Mr. Zamir also joining the Compensation Committee [2] New Board Members - Mr. Yitzhaik has over three decades of experience in retail and real estate, owning ASI Glasses and holding directorships in several publicly traded companies [3] - Mr. Zamir has extensive expertise in finance and capital markets, having served as CEO of an underwriting firm and CFO of a public real estate company, and currently leads M&A and financing activities in the renewable energy sector [4] Leadership Changes - Mr. Oz Adler has been appointed as the new Chairman of the Board, replacing Mr. Oren Shuster, who remains the Chief Executive Officer and a director [5] Strategic Review - The Company is conducting an ongoing strategic review and is exploring the introduction of additional business activities to enhance long-term growth opportunities and create further shareholder value [6] Company Overview - IM Cannabis Corp. is a leading medical cannabis company operating in Israel and Germany, focusing on sustainable and profitable growth in these high-value markets [7] - The Company operates a transnational ecosystem that includes importing and distributing cannabis, retail pharmacies, online platforms, and logistical hubs in Israel, as well as distributing cannabis to pharmacies in Germany through Adjupharm GmbH [8]

Core Points - IM Cannabis Corp. has regained compliance with Nasdaq Listing Rule 5550(b)(1), maintaining stockholders' equity of at least $2,500,000, allowing its common stock to continue trading on the Nasdaq Capital Market [1] Company Overview - IM Cannabis Corp. is an international cannabis company providing premium cannabis products to medical patients in Israel and Germany, two of the largest medical cannabis markets [2] - The company operates a transnational ecosystem powered by a data-driven approach and a globally sourced product supply chain, focusing on responsible growth and regulatory compliance [2] Operations - In Israel, IM Cannabis operates through subsidiaries that import and distribute cannabis to medical patients, utilizing proprietary data and patient insights [3] - The company runs medical cannabis retail pharmacies, online platforms, distribution centers, and logistical hubs in Israel to ensure safe delivery and quality control of its products [3] - In Germany, IM Cannabis operates through Adjupharm GmbH, distributing cannabis to pharmacies for medical cannabis patients [3]